ReviewUse of Bupropion in Combination with Serotonin Reuptake Inhibitors
Section snippets
Methods and Materials
This review is based on (1) MEDLINE searches of the past 8 years (up to March 2005, English language) to identify relevant case reports or studies included with original data in peer-reviewed journals and (2) abstracts and/or posters presented at meetings of the American Psychiatric Association and/or New Clinical Drug Evaluation Unit. Bibliographies of located articles and abstracts were searched for additional studies. Publications were selected for inclusion in this review if they included
Combination for Antidepressant Effects
Review of the literature revealed four prospective, open-label studies, three retrospective reviews, and multiple case reports describing the combination of bupropion with an SSRI or SNRI to augment the antidepressant effect of the original antidepressant in patients with partial or no response to SSRI, SNRI, or bupropion monotherapy (Table 1).
Discussion
Although the U.S. Food and Drug Administration has not approved the use of bupropion in combination with other antidepressants, combinations of bupropion with SSRIs or SNRIs are commonly used in clinical practice either to improve antidepressant response or to lessen sexual dysfunction. A modest but consistent body of evidence supports the efficacy of combining bupropion and SSRIs in treating depression refractory to either medication alone. In the published studies to date, response rates
References (46)
- et al.
Depression and public healthAn overview
J Psychosom Res
(2002) - et al.
Excess mortality in depressionA meta-analysis of community studies
J Affect Disord
(2002) - et al.
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study
Psychiatr Clin North Am
(2003) - et al.
Spontaneous orgasm with the combined use of bupropion and sertraline
Biol Psychiatry
(1996) - et al.
Major depressive disorderA prospective study of residual subthreshold depressive symptoms as predictor of rapid release
J Affect Disord
(1998) Depressive illness and disability
Eur Neuropsychopharmacol
(2000)- et al.
Depressive breakthrough
Psychiatr Clin North Am
(2000) - et al.
Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction
J Clin Psychiatry
(1998) - et al.
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy
J Clin Psychiatry
(1997) - et al.
Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants
J Clin Psychiatry
(2001)
Effect of bupropion on sexual dysfunction induced by fluoxetineA case report of hypersexuality
J Clin Psychiatry
Antidepressant-associated sexual dysfunctionA potentially avoidable therapeutic challenge
Primary Psychiatry
A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction
J Clin Psychiatry
Sexual dysfunction associated with the treatment of depressionA placebo-controlled comparison of bupropion sustained release and sertraline treatment
Ann Clin Psychiatry
Treating depressed primary care patients improves their physical, mental, and social functioning
Arch Intern Med
A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants
J Clin Psychopharmacol
ReManaging depression refractory to SSRIs
Can J Psychiatry
Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression
Ann Pharmacother
Bupropion sustained release as a treatment of SSRI-induced sexual side effects
J Sex Marital Ther
Bupropion for SSRI-induced fatigue
J Clin Psychiatry
Long-term outcome of episodes of major depression
JAMA
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetineA preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects
J Clin Psychiatry
Combination treatment with venlafaxine and bupropion
Am J Psychiatry
Cited by (107)
Characterization of the adrenocorticotrophic hormone - induced mouse model of resistance to antidepressant drug treatment
2017, Pharmacology Biochemistry and BehaviorDesign, synthesis and in vitro activity of 1,4-disubstituted piperazines and piperidines as triple reuptake inhibitors
2017, Bioorganic and Medicinal ChemistryThe VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations
2015, Psychiatry ResearchCitation Excerpt :It is effective for a broad spectrum of patients with MDD, including those with atypical, melancholic and anxious features (Thase et al., 2005; Papakostas et al., 2008), has low side effect burden, and has relatively low drug costs. Of special importance, bupropion-SR also has well-demonstrated efficacy and tolerability as an augmenting agent (Zisook et al., 2006). Evidence from STAR*D suggested that, as a switching agent, bupropion-SR was at least as effective as other commonly used SS/NRIs and, as an augmenting agent, is possibly more effective than other commonly used augmenting agents (Zisook et al., 2006).
Rodent models of treatment-resistant depression
2015, European Journal of PharmacologyA guide for addressing sexual health in breast cancer patients
2024, Journal of Surgical Oncology